Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Subscribe To Our Newsletter & Stay Updated
